Axentis Pharma AG

axentispharma.com

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA. To protect Axentis Pharma against loss and damage from malversations caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

KYAN THERAPEUTICS EXCLUSIVELY LICENSES SMALL MOLECULE HDAC INHIBITORS FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics, Inc. | September 24, 2020

news image

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More

Pharmacy Market

VIRIDIAN THERAPEUTICS ANNOUNCES PARTNERSHIP WITH DRUG DELIVERY INNOVATOR ENABLE INJECTIONS

Globenewswire | May 15, 2023

news image

Viridian Therapeutics, Inc. a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL. “As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that con...

Read More

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

news image

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More

Business Insights

FOSUN PHARMA AND INSILICO MEDICINE ANNOUNCE A STRATEGIC, AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION TO JOINTLY ADVANCE MULTIPLE TARGETS

Insilico Medicine | January 18, 2022

news image

Shanghai Fosun Pharmaceutical Co., Ltd, a leading innovation-driven international healthcare group in China and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (...

Read More
news image

KYAN THERAPEUTICS EXCLUSIVELY LICENSES SMALL MOLECULE HDAC INHIBITORS FOR AI-POWERED CANCER DRUG DEVELOPMENT

KYAN Therapeutics, Inc. | September 24, 2020

KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has already commenced preclinical development of the lead candidate, which has been designated as KYAN-001, with early positive results. In vitro and in vivo studies of KYAN-001 have shown high efficacy for Multiple Myeloma and Prostate ...

Read More
news image

Pharmacy Market

VIRIDIAN THERAPEUTICS ANNOUNCES PARTNERSHIP WITH DRUG DELIVERY INNOVATOR ENABLE INJECTIONS

Globenewswire | May 15, 2023

Viridian Therapeutics, Inc. a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse® innovative wearable drug delivery system for volumes of up to 25mL. “As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that con...

Read More
news image

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More
news image

Business Insights

FOSUN PHARMA AND INSILICO MEDICINE ANNOUNCE A STRATEGIC, AI-DRIVEN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION TO JOINTLY ADVANCE MULTIPLE TARGETS

Insilico Medicine | January 18, 2022

Shanghai Fosun Pharmaceutical Co., Ltd, a leading innovation-driven international healthcare group in China and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. This strategic collaboration includes an AI-driven drug discovery research and development (...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us